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The main objective of the present work was to enhance the solubility and dissolution rate of poorly 
water-soluble drug cefuroxime axetil (CA) by formulating it into solid dispersions (SDs) with water 
soluble carrier poloxamer 188. Different methods were employed to prepare the dispersion, such as: 
Solvent method (SM), Kneading method (KM), Melt evaporation method (MEM) and Physical mixture 
(PM) in different drug: carrier ratios 1:1, 1:2 and 1:3 (cefuroxime axetil: poloxamer 188). The physical 
mixture(s) and solid dispersion(s) were characterized for drug carrier interaction, drug content, solubility, 
dissolution rate, differential scanning calorimetry (DSC) and FT-IR study. The dissolution rate of the 
prepared solid dispersion systems was determined in phosphate buffer (pH 6.8) for 1 h. The solubility 
of drug from different systems was also determined in water. All SD formulations were found to have 
a higher dissolution rate comparatively to pure CA. The dissolution rate was enhanced in the following 
order SM > MEM > KM. The enhancement of dissolution rate may be caused by increase wettability, 
dispersibillity reduction in particle size or the formation of CA β crystalline. The FT-IR study probability 
revealed that there was no chemical interaction between drug and poloxamer 188. 
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INTRODUCTION
Over the last years, the number of poorly soluble 
drugs has significantly increased. Poorly water-
soluble drugs show unpredictable absorption, since 
their bioavailability depends upon dissolution in the 
gastrointestinal tract (Gorajana et al., 2015). Dissolution 
provides valuable information about bioavailability of 
the drug. It is considered to be one of the most important 
quality control tests performed on pharmaceutical dosage 
form (Razvi, Siddiqui, Khan, 2005). The important 
phenomenon in pharmaceutical formulation is “solubility” 
which plays very effective and significant role in the 
formulation of various dosage forms (Reddy et al., 2013). 
Aqueous solubility of a drug can be a critical limitation 
to its oral absorption. Poorly water-soluble drugs are 
associated with slow drug absorption leading eventually to 
inadequate and variable bioavailability. The enhancement 
of oral bioavailability of poorly water-soluble drugs 
remains one of the most challenging aspects of drug 
development (Prasanthi et al., 2011). Various techniques 
have been used to improve the solubility/dissolution rate 
of poorly water-soluble drugs (Jithendra et al., 2013). 
Solid dispersions have been widely used to enhance the 
solubility, dissolution rate, and bioavailability of poorly 
soluble drugs, there are different types of solid dispersion 
systems categorized according to the physical states of 
the drug and the carrier in the systems (Liu et al., 2006). 
Solid dispersion (SD) refers to a group of solid products 
consisting of at least two different components, generally 
a hydrophilic matrix and a hydrophobic drug. The matrix 
can be either crystalline or amorphous. The drug can 
be dispersed molecularly, in amorphous particles or in 
crystalline particles (Nokhodchi et al., 2007). In other 
words, SD involved a dispersion of one or more active 
ingredients in an inner carrier in solid state (Chaulang 
et al., 2008). Poloxamer block copolymers have been 
exploited in pharmaceutical formulations for solubilization 
of poorly water-soluble drugs. Poloxamers consist of an 
ethylene oxide hydrophilic core and polypropylene oxide 
hydrophobic core blocks arranged in a tri block structure 
resulting in an amphiphilic structure. Owing to their low 
melting point, they are suitable for the melt technique in 
solid dispersions. Their ability to self aggregate, thereby 
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forming micelles and liquid crystalline phases and greater 
hydrophilicity is another advantage for the solubilization 
of poorly water-soluble drugs. For drug delivery purposes, 
hydrophobic drugs may be solubilized within the core of 
the micelle or conjugated to the micelle forming polymer. 
These amphiphilic co-polymers are available in different 
grades as poloxamer 188 and poloxamer 407 (EI-Badry 
et al., 2013). Poloxamer 188 was used to enhance the 
dissolution rate of several drugs such as cefuroxime 
axetil, sulfadiazine, sulfisoxazole, sodium diclofenac and 
midazolam (Sruti et al., 2013; Reddy, Khalil, Gouda 1976; 
Datta, Kaur, 2014; Jithendra et al., 2013). Cefuroxime 
(CA), a semi-synthetic broad-spectrum 2nd generation 
cephalosporin, is among one of the antibiotics widely 
used to treat bacterial infections (Dellamonica, 1994). 
Besides treating lower respiratory tract infections, CA 
may also be used to treat upper respiratory tract infections, 
skin and soft tissue infections, and genitourinary tract 
infections caused by susceptible bacteria. It may also be 
employed for prophylaxis purposes in conditions such 
as coronary artery bypass grafting surgery or elective 
cholecystectomy (Pichichero, 2007). Cefuroxime axetil, 
Chemically, 1-acetoxyethyl (6R,7R)-3-[(carbamoyloxy)
methyl]-7-{[(2Z)-2-(2-furyl)-2-(methoxyimino)acetyl]
amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-
carboxylate (See Figure 1), is an oral prodrug of the 
bactericidal cephalosporin antibiotic cefuroxime, which 
is resistant to degradation by most β-lactamases and is 
active against a wide range of Gram-positive and Gram-
negative organisms. It is used frequently for pediatric 
conditions like upper respiratory tract infections (Vinod, 
Chenthilnathan, 2013). Cefuroxime axetil is slightly 
soluble in water (British Phamacopoeia, 2009), and its 
poor aqueous solubility and wettability gives rise to 
difficulties in pharmaceutical formulations for oral and 
parenteral delivery. The aim of the present investigation 
was to enhance the solubility, dissolution rate of CA 
with solid dispersion technique using Poloxamer 188 
as a hydrophilic carrier, and evaluated the effect of it on 
solubility profile of the drug. Solid dispersion systems of 
the drug with Poloxamer 188 were prepared in different 
ratios by solvent, kneading and melt evaporation 
techniques. The physicochemical properties of the 
prepared solid dispersion were evaluated using different 
methods.
MATERIAL AND METHODS
Materials
Pure cefuroxime axetil (CA) and poloxamer 188 were 
obtained as gratis sample from DIAMOND PHARMA, 
Syria. Sodium dihydrogen phosphate and Disodium 
hydrogen phosphate of AR grade and other chemicals of 
AR grade were purchased from E. Merck® (Germany).
Preparation of CA solid dispersions (SDs) using 
different techniques
Different drug: polymer ratios (1:1, 1:2 and 1:3) 
(Table I) were used for preparing CA solid dispersions 
in Poloxamer 188 matrix, via melt evaporation method 
(MEM), solvent method (SM) and kneading method (KM).
Solvent method (SM)
In this method, the weighed amounts of CA and 
polymer dissolved in a minimum amount of methanol. FIGURE 1 - Structural formula of cefuroxime axetil.
TABLE I – Drug-carrier weight ratio in prepared formulations. 
CA is pure cefuroxime axetil, S1 to S3 are solid dispersions 
(SM), K1 to K3 are solid dispersions (KM), M1 to M3 are solid 
dispersions (MEM) and P1 to P3 are physical mixtures
Formulation code Drug: Carrier ratio
CA 1:0
S1 1:1
S2 1:2
S3 1:3
K1 1:1
K2 1:2
K3 1:3
M1 1:1
M2 1:2
M3 1:3
P1 1:1
P2 1:2
P3 1:3
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Then, the organic solvents were removed by evaporation 
at room temperature. The dried mass was taken, pulverized 
and sieved. The samples were kept in desiccators until the 
experiment (EI-Badry et al., 2013).
Kneading method (KM)
In this method, the weighed amounts of CA and 
polymer kneaded with appropriate amounts of methanol 
using a mortar and pestle for 10 min. The mass was dried 
(room temperature overnight), crushed, sieved and dried 
again in an oven at 40 °C for 24 h (EI-Badry et al., 2013).
Melt evaporation method (MEM)
In this method accurately weighed of CA is 
dissolved in a minimum amount of methanol. The 
solution is incorporated into the melt of polymer. Then, 
the organic solvents were removed by evaporation until a 
clear, solvent free film is left. The film is further dried to 
constant weight and mass is kept in desiccators until the 
experiment.
Preparation of physical mixture
The physical mixtures were prepared by weighing 
cefuroxime axetil and poloxamer 188 and mixing them. 
The formulations were obtained by mixing the components 
using spatula in a mortar for 5 minutes. They were passed 
through 50-mesh sieve and kept in desiccators until the 
experiment.
CHARACTERIZATION OF SOLID 
DISPERSIONS
Drug content
A fixed amount of pure CA (150.3 mg) and CA SDs 
equivalent to 150.3 mg of pure CA were weighed and 
dissolved homogenously with methanol. The solution was 
suitably diluted and the absorbance was measured at 280 
nm. Drug content was calculated using the appropriate 
equation.
In-vitro dissolution rate testing
Pure CA, CA SDs, and CA physical mixtures 
equivalent to 150.3 mg of pure CA were tested for their 
dissolution profile individually in dissolution vessels for a 
period of 1h in 900 mL phosphate buffer pH 6.8 maintained 
at 37±0.5 °C under 50 rpm stirring rate (Pharma test DT 
70, Germany). During this period, 10 mL of samples were 
withdrawn at regular intervals of time and analyzed using 
Ultraviolet-Vis spectrophotometer (UV- SHIMADZU 
1800) at 280 nm. The amount of drug released was 
calculated using the appropriate equation.
Solubility studies
A fixed amount of pure CA (150.3 mg) and CA SDs 
equivalent to 150.3 mg of pure CA were weighed. These 
weighed samples were sealed tightly and mix with distilled 
water using an ultrasonicator at 40 °C for 1h. Following 
that, these conical tubes were removed and transferred into 
a shaking incubator, which was set to operate at 37 °C, 100 
rpm for 24 h. After 24 h, the shaker was switched off while 
the conical tubes were left in the incubator for another 12 
h, incubating at 37 °C. The absorbance values for each 
sample were measured at 280 nm, in duplicate (Gorajana 
et al., 2015).
ATR- FTIR spectroscopy
(ATR- FTIR) spectroscopy is used to assess the 
interaction between carrier or complexing agent and guest 
molecule in solid state. ATR-FTIR studies: Spectra for pure 
CA, Poloxamer 188 and solid dispersions were recorded 
in a FT-IR (BRUKER- TENSOR 27) spectrophotometer.
Preparation of standard curve
50 mg of drug was dissolved in 100 mL methanol 
to produce 500 μg/mL stock solution. From the stock 
solution, 0.5 mL is pipette out in to 100 mL volumetric 
flask and made up to the volume with phosphate buffer 
(pH 6.8). Further dilutions were made to produce different 
concentrations from 2.5-20 μg/mL. Standard solutions 
were then analyzed by Ultraviolet-Vis spectrophotometer 
(UV- SHIMADZU 1800) at 280 nm and absorbance was 
noted. Then the absorbance values were plotted against 
drug concentration and standard curve of cefuroxime 
axetil was produced.
Differential scanning calorimetry (DSC) analysis
Calorimetric studies of the drug and the prepared 
solid dispersion systems were performed using a DSC-20 
(METTLER TOLEDO, Switzerland). All accurately 
weighed samples were placed in sealed aluminium pans 
before heating under nitrogen flow (100 mL/min) at a 
scanning rate of 10°/min from 25 to 300°. 
T. Sankari, S. Al-Hariri
Braz. J. Pharm. Sci. 2018;54(4):e17644Page 4 / 10
Kinetic analysis of drug release
The dissolution profiles of all the SDs were 
subjected to the kinetic analysis to establish the drug-
release mechanism. The release data were fitted to zero 
order (equation 1), first order (equation 2) and matrix 
(Higuchi model) (equation 3) to ascertain the kinetic 
modeling of drug release (Gorajana et al., 2015).
 Qt = k0t (1)
 In Qt = In Q0 – k1t (2)
 Qt = kHt1/2 (3)
Micromeritic properties of powder blends
Micromeritic properties i.e. bulk density (ρb), tapped 
density (ρt), compressibility index (CI) and Hausner ratio 
(HR) of the blended powder were determined by the 
following formulas under BP2009 guidelines.
ρb = M (weight of the powder blend) / Vb (bulk volume)  (1)
ρt = M (weight of the powder blend) / Vt (tapped volume)  (2)
CI = (ρt - ρb) / ρt x 100   (3)
HR = ρt/ρb   (4)
RESULT AND DISCUSSION
In vitro dissolution studies
The dissolution profiles of CA-Poloxamer-188 solid 
dispersions (SDs) prepared using different methods for 
CA were compared to those of the PM and drug itself. The 
dissolution study showed that the release percentage of 
pure CA after one hour was only 37.8% (Table II). During 
dissolution studies, it was noted that drug carrier systems 
sink immediately, whereas pure drug keeps floating on 
the surface for a longer time interval. There was an appeal 
difference between the release rate of pure CA and solid 
dispersions. Comparative dissolution profile showed that 
an increase in the percentage of Poloxamer 188 resulted in 
an increase in the release rate of CA. All the prepared SD 
systems showed a remarked enhancement of the in-vitro 
drug dissolution rate. In particular, SD systems prepared 
by Solvent method in ratio 1:3 was able to produce 79.59 % 
of the drug in solution, while the melt evaporation method 
produce about 73.06 % and the Kneading method produce 
about 66.94% of the drug in solution within one hour. On 
the other hand, the PM produced about 38.37 % of the 
drug in solution. It could be seen that, Poloxamer-188 has 
effectively enhanced the drug dissolution and this effect 
depended on the ratio of the carrier used and the method 
of the preparation of solid dispersion. (Figure 6) showed 
the comparison between the dissolution behavior of the 
drug from all different systems. It has shown that the 
Solvent method had the priority of the enhancing of the 
dissolution rate. It is evident that, in all solid dispersion 
preparation methods, increasing the Poloxamer-188 
weight ratio was followed by increasing the amount of 
CA dissolved. The enhancement of dissolution of CA 
from solid dispersion systems may be due to lack of 
crystallinitty, amorphization, increase wettability and 
dispersibility and particle size reduction (EI-Badry et al., 
TABLE II - Drug release pattern of various formulations
Time (min)
5 10 15 25 30 40 50 60
%
 D
ru
g 
re
le
as
e
CA 27.4±0.60 28.6±0.96 29.8±0.54 35.0±0.59 36.5±0.84 36.8±1.09 37.2±0.53 37.8±0.90
S1 26.7±0.50 37.8±0.57 38.8±0.85 42.7±0.44 44.1±0.86 49.0±0.60 49.8±0.59 48.0±0.40
S2 37.4±0.64 41.8±0.74 45.3±0.69 47.0±0.36 53.3±0.38 53.1±0.50 54.3±0.38 52.7±0.80
S3 73.3±0.99 76.5±0.72 77.2±0.60 78.6±1.00 79.6±1.02 78.0±0.40 76.1±0.64 75.5±0.50
M1 16.3±0.40 15.5±0.85 22.1±0.56 21.0±0.72 24.0±0.70 27.0±0.84 30.2±0.42 31.0±0.76
M2 65.3±0.64 71.0±0.72 73.0±0.79 71.4±0.69 73.0±0.42 72.0±0.95 74.0±0.78 74.5±0.76
M3 69.3±0.57 71.4±0.56 72.0±0.59 70.2±0.59 71.2±0.93 73.0±0.64 71.2±0.67 72.5±0.90
K1 35.1±0.72 45.0±0.61 44.5±0.84 48.0±0.29 48.3±0.49 52.2±0.45 57.0±0.61 57.1±0.44
K2 49.0±0.58 60.4±0.51 61.2±0.41 64.3±0.38 65.3±0.58 66.3±0.93 65.7±0.59 66.0±0.41
K3 60.4±0.76 63.0±0.66 62.1±0.92 63.1±0.72 63.3±0.76 66.1±0.64 67.0±0.64 66.3±0.84
P1 16.3±0.56 16.7±0.75 18.0±0.47 23.5±0.74 26.5±0.72 27.4±0.49 28.8±0.64 29.0±0.55
P2 22.3±0.51 27.8±0.81 28.6±0.70 30.2±0.80 32.7±0.47 33.3±0.76 33.9±0.58 34.3±0.46
P3 27.6±0.71 31.8±0.41 32.2±0.43 32.7±0.60 36.7±0.70 37.1±0.64 37.8±0.99 38.4±0.64
Each value is a Mean±SE of three determination.
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2013). Furthermore, Solvent method produces a uniform 
distribution of drug in the copolymer carrier crust in 
highly dispersed state. Thus, when such system becomes 
in contact with dissolution medium, the hydrophilic 
carrier dissolves rapidly. In addition, the Poloxamer-188 
has surface activity so it reduces the interfacial tension 
between the solid dispersion and dissolution medium 
and decreases the aggregation of drug particles and 
enhances the dissolution rate of drug. The dissolution of 
the physical mixtures was higher compared to pure CA. 
FIGURE 2 - In vitro dissolution profiles of cefuroxime axetil and physical mixtures.
FIGURE 3 - In vitro dissolution profiles of cefuroxime axetil and solid dispersions prepared by solvent method.
FIGURE 4 - In vitro dissolution profiles of cefuroxime axetil and solid dispersions prepared by melt evaporation method.
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SDs of CA in hydrophilic carrier considerably enhanced 
dissolution compared to the physical mixtures. (Jafar, Mhg 
and Shareef 2010) study showed the solid dispersions of 
Meloxicam with PEG 6000 improved dissolution when 
compared with physical mixtures and pure drug.
Drug content
The drug content was found in the range of 90.6±1.14 
to 95.7±0.91 indicating the acceptability of method for 
preparation of solid dispersions. drug content of the 
prepared solid dispersions has been shown in Table III.
Standard curve
The drug evaluated for formulation before their 
formulation. Standard Calibration Curve of Cefuroxime 
Axetil was prepared in phosphate buffer (pH 6.8) at λmax 
280 nm (Table IV). The standard curve of cefuroxime 
axetil produced is as shown in (Figure 7) (Pande, Biyani, 
2017).
Solubility study
The solubility studies of CA and its various 
formulations are shown in Table V. all formulations of 
SD had statistical significantly better solubility compared 
FIGURE 5 - In vitro dissolution profiles of cefuroxime axetil and solid dispersions prepared by kneading method.
FIGURE 6 - Comparative in vitro dissolution profiles of solid dispersions (1:3) prepared by three methods with pure drug.
TABLE III - Drug content of the various solid dispersions 
prepared
Formulation code Drug content %
S1 91.3±1.40
S2 90.6±1.14
S3 90.9±0.93
M1 92.4±1.04
M2 91.2±0.62
M3 92.2±0.86
K1 95.7±0.98
K2 94.8±0.99
K3 95.7±0.91
Each value is a Mean±SE of three determination.
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with pure CA. The increase in solubility with increasing 
poloxamer concentration indicates the solvent properties 
of poloxamer 188 for the drug. Poloxamer 188 causes 
a decrease of interfacial tension between the drug and 
solubility medium. These results could be explained that 
the reduction in crystallinity of drug led to a decrease of 
the energy required in the dissolving process and also to a 
highly dispersed state of the drug (Prasanthi et al., 2011).
FTIR analysis
FTIR spectroscopy analysis was done to analyze 
physico-chemical interactions between cefuroxime axetil 
and poloxamer 188 in form of solid dispersions. (Figure 
8) represents the FTIR spectra and characteristic wave 
numbers of cefuroxime axetil and poloxamer 188. The 
IR spectrum of CA shows two carbonyl absorption bands 
at 1677.25 cm-1, assigned to amide carbonyl stretching. 
There were two absorption peak at 3474.47 and 1778 cm-1 , 
assigned to secondary N-H stretching vibration and a C=O 
stretching of vinyl ester. Poloxamer 188 spectrum showed 
characteristic peaks at 3447.94, 2883.23, and 1101.81 cm-1 
due to stretching of O–H, C–H, and C–O groups. 
In the spectra of all physical mixture and SD 
formulations, major characteristic peaks of both drug 
individually and polymer were retained. We expect 
that there was no chemical interactions amongst the 
components of the formulation and compatibility of the 
drug with the carrier (Arora et al., 2010; Dua et al., 2011). 
The study indicates that CA Probability has strong physical 
interaction with poloxamer 188 in solid state. FTIR 
spectroscopy revealed the possibility of inter-molecular 
hydrogen bonding in solid dispersions (Jun et al., 2005; 
Sharma, Jain, Tanwar, 2013).
Differential scanning calorimetry (DSC) analysis
Differential scanning calorimetry (DSC) is frequently 
used in the pharmaceutical field as a thermal analysis 
technique, to provide detailed information about both the 
FIGURE 7 - Standard curve of cefuroxime axetil in phosphate buffer (pH 6.8).
TABLE IV – Standard Calibration curve of cefuroxime axetil
Concentration (μg/mL) Absorbance (nm) 
2.5 0.094±0.009
5 0.195±0.006
10 0.372±0.004
15 0.560±0.004
20 0.752±0.003
Each value is a Mean±SE of three determination.
TABLE V - Solubility of CA and its formulations
Formulation code Solubility %
CA 39.1±0.97
S1 77.2±0.97
S2 60.7±0.81
S3 66.7±0.91
M1 68.8±0.67
M2 78.8±0.84
M3 64.3±0.84
K1 53.6±0.88
K2 59.3±0.74
K3 64.3±0.66
Each value is a Mean±SE of three determination.
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physical and energetic properties of substances (EI-Badry 
et al., 2013). (Figure 9) represents the DSC thermograms 
of CA, poloxamer 188 and SDs of CA (formulation S3, M3 
and K3). In the thermogram of poloxamer 188, a sharp peak 
(54.18°C) was observed, which was associated with the 
endothermic melting of poloxamer 188. Whereas, the DSC 
thermogram of CA exhibited a sharp endothermic peak at 
86.36° and 179.56° and exothermic peak at 217.69°. The 
position of the melting peak of poloxamer 188 remained 
largely unchanged, while that of CA shifted depending 
on the concentration of polymer. At a ratio of (1:3), the 
endothermic peak of CA was no longer observed. This 
FIGURE 8 - IR spectrum of cefuroxime axetil, poloxamer 188, and their formulations.
FIGURE 9 - Differential scanning calorimetric thermograms of cefuroxime axetil, poloxamer 188, and their formulations.
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could be because CA was molecularly or amorphously 
dispersed in the phases (Liu et al., 2006). It is worthy 
to note that the DSC Studies indicate that CA has been 
transformed to an amorphous or less crystalline form in 
its-polymer SD systems.
Kinetic analysis of drug release
The release data were fitted to various kinetic models 
in order to calculate the release constant and regression 
coefficients (R2) as seen in Table VI. A higher correlation, 
as indicated by R2 was observed for the Higuchi matrix 
release kinetics in all the selected formulations suggesting 
the diffusion as a probable prominent mechanism of 
drug release. In diffusion, the rate of dissolution of drug 
particles within the matrix must be much faster than that 
of the diffusion rate of drug leaving the matrix (Gorajana 
et al., 2015; Joshi, Bolmal, Dandagi, 2014).
Evaluation of powder blends and tablets
In order to obtain optimum flow characteristics of 
powder, blends of each formulations (S3, M3, K3) were 
evaluated for bulk density, tapped density, compressibility 
index and Hausner’s ratio as shown in Table VII. The 
results indicated that all powder blends showed excellent 
flow characteristics according to BP 2009; ranged from 
3.77% – 7.69% for Carr’s index, and 1.04 – 1.08 for 
Hausner’s ratio. Excellent flow of the blends might be 
due to appropriate composition of poloxamer 188 in all 
formulations (Israr et al., 2014). 
CONCLUSION
In this paper, an increased solubility and dissolution 
rate of cefuroxime axetil were achieved by forming a 
solid dispersion using poloxamer 188 as a carrier. Solid 
dispersions demonstrated a higher dissolution rate than 
physical mixtures and pure drug. The enhancement of 
dissolution rate may be caused by increase wettability, 
dispersibility reduction in particle size or the formation 
of CA β crystalline. The FT-IR study probability revealed 
that there was no chemical interaction between drug and 
poloxamer 188. Solubility studies showed a solubilizing 
effect of poloxamer 188 on cefuroxime axetil. The solid 
dispersion technique used in our study involves relatively 
simple preparation steps and can be used for preparing 
granules, tablets and capsules.
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TABLE VI - Release kinetics data of CA and its formulations
Sample Zero Order  (R2)
First Order 
(R2)
Higuchi 
(R2)
S1 0.5949 0.6770 0.8457
S2 0.5033 0.5936 0.7707
S3 0.2303 0.2340 0.4901
M1 0.7625 0.8100 0.9286
M2 0.2935 0.3599 0.5584
M3 0.2456 0.2676 0.4996
K1 0.5722 0.6916 0.8175
K2 0.3898 0.4796 0.6695
K3 0.3049 0.3686 0.5648
P1 0.7268 0.7700 0.9220
P2 0.5176 0.5680 0.7836
P3 0.4777 0.5345 0.7418
TABLE VII - Micromeritic properties of cefuroxime axetil solid dispersions
Sample Mass(g)
Bulk 
Volume
(mL)
Tapped 
Volume
(mL)
Bulk 
Density
(g/mL)
Tapped 
Density
(g/mL)
Compressibility 
Index
(%)
Hausner 
Ratio
S3 2.53 5.20 4.90 0.4865 0.5163 5.77 1.06
M3 2.82 5.30 5.10 0.5321 0.5529 3.77 1.04
K3 2.89 6.50 6.0 0.4446 0.4817 7.69 1.08
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